Syneron to Launch Industry-First Treatment Modality, New Product for Procedures Leading to Body Contouring and Physician-Focused
03 Junio 2009 - 8:00AM
Marketwired
Syneron Medical Ltd. (NASDAQ: ELOS), http://www.syneron.com, a
leading innovator in medical aesthetic devices, will unveil three
groundbreaking initiatives at THE Aesthetic Show in Las Vegas, June
5-7. The company will introduce a new and unique treatment modality
called Sublative Rejuvenation(TM), which answers the skin
rejuvenation market's emerging demand for optimal efficiency,
minimal downtime and an affordable procedure price point. In
addition, Syneron will release VelaShape II(TM), with increased RF
energy for quicker non-invasive procedures leading to body
contouring, and launch Syneron Advantage(TM) -- a new physician
partnership program to support customers' financial and business
needs in today's economic climate.
Recent scientific evaluations using eMatrix(TM),
http://www.syneron.com/products/ematrix, led to the identification
of Sublative Rejuvenation, a new treatment modality that goes
beyond current fractional skin ablation and resurfacing methods.
Sublative Rejuvenation utilizes RF sublation, a fractionated
bi-polar radio frequency technology in which heat energy is
effectively placed into the dermis, producing significant dermal
remodeling with the least amount of epidermal disruption. While
traditional fractional technologies are most aggressive at the
epidermal level, Sublative Rejuvenation delivers energy creating a
triangular-shaped pattern of impact where the ablated zone on the
skin's surface is narrower. The ablative and particularly
coagulative zone widens below the surface, reflecting the higher
heating of layers of the dermal connective tissue and collagen.
This specific, sublative targeting maximizes clinical results and
reduces downtime and risk of adverse reaction. Increased dermal
heating leads to stronger collagenesis, making Sublative
Rejuvenation most desirable for wrinkle reduction as well as
overall textural improvement and luminosity for all skin types.
"Before the introduction of Sublative Rejuvenation with eMatrix,
I needed to be extremely careful when performing any kind of
ablative or even non-ablative treatment on my patients with darker
skin tones because of possible adverse reactions," said Hema
Sundaram, M.D., F.A.A.D., a board certified dermatologist in
Washington, D.C. "In my experience with eMatrix, there have been no
cases of post-inflammatory hyperpigmentation, the most common
complication observed when performing any type of laser resurfacing
treatment on patients with darker skin tones. This finding is
unique and extremely exciting."
Building on the experience of more than three million procedures
by the company's physician partners, Syneron's global, non-invasive
body contouring leadership continues to advance with the
introduction of VelaShape II. The latest device on the market for
cellulite and circumferential reduction leading to body contouring,
VelaShape II offers current and new practitioners added features
and benefits, including increased power for shorter treatment
sessions, reduced number of sessions, and an advanced Clever(TM)
terminal, a diagnostic digital user interface to improve both
consistency in treatment results and patient comfort.
In conjunction with these two treatment and product
developments, Syneron launches the Syneron Advantage program,
http://www.syneronadvantage.com. The program enables physicians to
gain access to Syneron facial applications and body shaping
technologies at a more affordable price point that are easier to
finance in the current economic environment. The Syneron Advantage
program also delivers services and programs to further support the
success of physicians long after purchase. The program is now
available with purchases of new VelaShape II(TM), LipoLite(TM) and
eMatrix(TM) devices.
"At Syneron, our customer focus goes well beyond developing
superior technology for aesthetic treatments," said Syneron CEO Lou
Scafuri. "The Syneron Advantage program takes Syneron's commitment
to our customer's success to a new level by directly addressing
cost-of-acquisition and cost-of-ownership considerations to help
ensure the physician's long-term success with Syneron's aesthetic
devices."
For more information on Syneron presentations at THE Aesthetics
Show, please visit
http://promotions.syneron.com/email/2009/Q2/330-tasvegas_speakers/new/.
About Syneron
Syneron Medical Ltd. (NASDAQ: ELOS) manufactures and distributes
medical aesthetic devices that are powered by the proprietary,
patented elos(TM) combined-energy technology of bi-polar radio
frequency and light. The company's innovative elos technology
provides the foundation for highly effective, safe and
cost-effective systems that enable physicians to provide advanced
solutions for a broad range of medical-aesthetic applications
including hair removal, wrinkle treatment , rejuvenating the skin's
appearance through the treatment of superficial benign vascular and
pigmented lesions, the treatment of acne, leg veins, cellulite and
(thighs) circumferences reduction, as well as laser assisted
lipolysis. Founded in 2000, the corporate, R&D, and
manufacturing headquarters for Syneron Medical Ltd. is located in
Israel. Syneron has offices and distributors throughout the world,
including North American headquarters in Irvine, California, and
Asia-Pacific headquarters in Hong Kong, which provide sales,
service and support. Additional information can be found at
http://www.syneron.com.
Syneron, the Syneron logo, eMatrix, VelaShape, Clever, Sublative
Rejuvenation and elos are trademarks of Syneron Medical Ltd. and
may be registered in certain jurisdictions. Elos (Electro-Optical
Synergy) is a proprietary technology of Syneron Medical. All other
names are the property of their respective owners.
For more information, please contact: Elin Nozewski Airfoil PR
for Syneron 248-304-1412 Email Contact
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024